These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29580376)

  • 1. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
    Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
    Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis.
    Yang H; Llewellyn A; Walker R; Harden M; Saramago P; Griffin S; Simmonds M
    BMC Med; 2019 Feb; 17(1):37. PubMed ID: 30760268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
    Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
    BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
    Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
    BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
    Szczepura A; Osipenko L; Freeman K
    BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antenatal
    Clausen FB
    Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews.
    Ryczek E; White J; Carolan-Rees G
    Transfus Med; 2020 Aug; 30(4):287-294. PubMed ID: 32447792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Rh alloimmunization.
    Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
    J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands.
    de Haas M; Thurik FF; van der Ploeg CP; Veldhuisen B; Hirschberg H; Soussan AA; Woortmeijer H; Abbink F; Page-Christiaens GC; Scheffer PG; Ellen van der Schoot C
    BMJ; 2016 Nov; 355():i5789. PubMed ID: 27821701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status.
    Legler TJ; Lührig S; Korschineck I; Schwartz D
    Arch Gynecol Obstet; 2021 Nov; 304(5):1191-1196. PubMed ID: 33835210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
    Kent J; Farrell AM; Soothill P
    BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of fetal RHD type in plasma of RhD negative pregnant women.
    Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
    Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.